Medical University of Gdansk

gumed.edu.pl

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

125

Active

38

Phase 3

4

Total enrollment

125,902

Pipeline matrix

Showing 17 of 17 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
remimazolam sedation reversal with flumazenil1
Ticagrelor1
Dabigatran Etexilate1
Aspirin1
Clopidogrel1
Palbociclib1
Paclitaxel1
Carboplatin1
Clozapine1
Ketamine Hydrochloride1
Intensified intravenous omeprazole therapy1
Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).1
Apixaban1
Rivaroxaban1
low molecular weight heparin1
Cholecalciferol1
Different drug type for conduction of general anesthesia1

Next readouts

  • 2024-12-31
  • 2025-01-01
  • 2026-04-01
  • 2026-04-30
  • 2026-07-11
  • 2026-12-31
  • 2027-06
  • 2027-10
  • 2029-12-31

Top conditions

  • Chronic Kidney Disease5
  • Proteinuria5
  • Healthy4
  • Acute Kidney Injury4
  • Manual Therapy3
  • Manipulation3
  • Muscles3
  • Major Depressive Disorder3

Frequently asked questions about Medical University of Gdansk

How many clinical trials does Medical University of Gdansk have on ClinicalTrials.gov?
Medical University of Gdansk is listed as the lead sponsor on 125 clinical trials in ClinicalTrials.gov, 38 of which are currently active (recruiting, enrolling, or ongoing).
How many of Medical University of Gdansk's trials are in Phase 3?
4 of Medical University of Gdansk's trials are in Phase 3, spread across 17 active drug programs.
What therapeutic areas does Medical University of Gdansk focus on?
Medical University of Gdansk's most-studied conditions on ClinicalTrials.gov are Chronic Kidney Disease, Proteinuria, Healthy, Acute Kidney Injury, Manual Therapy.
When are Medical University of Gdansk's next clinical trial readouts?
Medical University of Gdansk has 9 upcoming primary-completion readouts tracked here; the soonest is “Observation of Clozapine Treatment Safety in Bipolar Disorder.”, expected around 2024-12-31.